Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Bagnolini G, Milano D, Manerba M, Schipani F, Ortega JA, Gioia D, Falchi F, Balboni A, Farabegoli F, De Franco F, Robertson J, Pellicciari R, Pallavicini I, Peri S, Minucci S, Girotto S, Di Stefano G, Roberti M, Cavalli A. Bagnolini G, et al. Among authors: pallavicini i. J Med Chem. 2020 Mar 12;63(5):2588-2619. doi: 10.1021/acs.jmedchem.9b01526. Epub 2020 Feb 24. J Med Chem. 2020. PMID: 32037829 Free PMC article.
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.
Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, Pelicci PG, Chiocca S, Johnstone RW, Minucci S. Santoro F, et al. Among authors: pallavicini i. Blood. 2013 Apr 25;121(17):3459-68. doi: 10.1182/blood-2012-10-461988. Epub 2013 Feb 25. Blood. 2013. PMID: 23440245 Free article.
Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.
Falchi F, Giacomini E, Masini T, Boutard N, Di Ianni L, Manerba M, Farabegoli F, Rossini L, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Roberti M, Pellicciari R, Cavalli A. Falchi F, et al. Among authors: pallavicini i. ACS Chem Biol. 2017 Oct 20;12(10):2491-2497. doi: 10.1021/acschembio.7b00707. Epub 2017 Sep 1. ACS Chem Biol. 2017. PMID: 28841282 Free article.
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A. Roberti M, et al. Among authors: pallavicini i. Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10. Eur J Med Chem. 2019. PMID: 30660828
Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition.
Cazzoli R, Romeo F, Pallavicini I, Peri S, Romanenghi M, Pérez-Valencia JA, Hagag E, Ferrucci F, Elgendy M, Vittorio O, Pece S, Foiani M, Westermarck J, Minucci S. Cazzoli R, et al. Among authors: pallavicini i. Cell Rep. 2023 Jun 27;42(6):112616. doi: 10.1016/j.celrep.2023.112616. Epub 2023 Jun 7. Cell Rep. 2023. PMID: 37289585 Free article.
Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms.
Cella CA, Cazzoli R, Fazio N, De Petro G, Gaudenzi G, Carra S, Romanenghi M, Spada F, Grossi I, Pallavicini I, Minucci S, Vitale G. Cella CA, et al. Among authors: pallavicini i. Endocr Relat Cancer. 2023 Oct 18;30(12):e230232. doi: 10.1530/ERC-23-0232. Print 2023 Dec 1. Endocr Relat Cancer. 2023. PMID: 37855330 Free PMC article.
24 results